金刚烷胺治疗帕金森病的有效性和安全性评价

Effectiveness and Safety of Amantadine in Parkinson Disease——a Meta-Analysis

目的评价金刚烷胺治疗帕金森病的有效性和安全性。方法计算机检索Cochrane图书馆、PubMed数据库、Embase数据库、ISI数据库、CBM数据库、CNKI数据库、VIP数据库、万方数据库,纳入金刚烷胺对比安慰剂治疗帕金森病的随机对照试验(RCT)、系统评价(SR)和Meta分析,对纳入的随机对照试验进行方法学质量评价和Meta分析,参考纳入的系统评价和Me-ta分析结论。结果与结论金刚烷胺与安慰剂对照治疗帕金森病共纳入9个RCT。结果显示,金刚烷胺治疗帕金森病有效率高于安慰剂组,差异有统计学意义[RR 10.13,95%CI(5.10,20.11)],P<0.000 01。改善帕金森症状差异有统计学意义[RR-3.21,95%CI(-5.88,-0.54)],P=0.02;ADR差异无统计学意义。

OBJECTIVE To evaluate the effectiveness and safety of amantadine in Parkinson＇ s disease. METHODS Cochrane library, Pubmed database, Embase database, ISI database, CBM database, CNKI database, VIP database, Articles Database in com- puter were searched. Randomized controlled trials （RCT）, systematic review （SR） or Meta analysis of amantadine vs placebo in Parkinsong disease were selected, then quality evaluation and Meta-analysis were performed. The conclusions of the included SR and Metaanalysis were taken into consideration. RESULTS There were 9 RCTs of amantadine vs placebo in treating parkinsong disease. The result showed that the efficacy of amantadine was better than placebo [ RR 0. 14,95% CI （0. 06, 0. 29）, P 〈0. 000 01 ]. Amantadine was better than placebo to improve parkinson＇s symptoms [ RR - 3.21,95% CI （ - 5.88, - 0. 54）, P = 0. 02 ]. When it comes to ADR, there was no significant difference between amantadine and placebo.